#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dexamethasone

Contact Research Centre

Prostate cancer metastatic

Recruiting

Registered drug

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Registered drugNo placebo

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Infliximab

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Lenalidomide

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Registered drugNo placebo

Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Argipressin

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Hormone-refractory prostate cancer

Not recruiting

Registered drugNo placebo

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone

Contact Research Centre

Interstitial lung disease+1

Not recruiting

Investigational

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.